Literature DB >> 33854239

The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D.

Andrea C Chaikovsky1,2, Chuan Li3, Edwin E Jeng2, Samuel Loebell1,2, Myung Chang Lee1,2, Christopher W Murray2,4, Ran Cheng3, Janos Demeter5, Danielle L Swaney6,7,8, Si-Han Chen6,7,8, Billy W Newton6,7,8, Jeffrey R Johnson6,7,8, Alexandros P Drainas1,2, Yan Ting Shue1,2, Jose A Seoane2,9, Preethi Srinivasan2,9, Andy He1,2, Akihiro Yoshida10,11, Susan Q Hipkins1,2, Edel McCrea1,2, Carson D Poltorack1,2, Nevan J Krogan6,7,8, J Alan Diehl10,11, Christina Kong4, Peter K Jackson5, Christina Curtis2,9, Dmitri A Petrov3, Michael C Bassik2, Monte M Winslow2,4, Julien Sage12,13.   

Abstract

The initiation of cell division integrates a large number of intra- and extracellular inputs. D-type cyclins (hereafter, cyclin D) couple these inputs to the initiation of DNA replication1. Increased levels of cyclin D promote cell division by activating cyclin-dependent kinases 4 and 6 (hereafter, CDK4/6), which in turn phosphorylate and inactivate the retinoblastoma tumour suppressor. Accordingly, increased levels and activity of cyclin D-CDK4/6 complexes are strongly linked to unchecked cell proliferation and cancer2,3. However, the mechanisms that regulate levels of cyclin D are incompletely understood4,5. Here we show that autophagy and beclin 1 regulator 1 (AMBRA1) is the main regulator of the degradation of cyclin D. We identified AMBRA1 in a genome-wide screen to investigate the genetic basis of  the response to CDK4/6 inhibition. Loss of AMBRA1 results in high levels of cyclin D in cells and in mice, which promotes proliferation and decreases sensitivity to CDK4/6 inhibition. Mechanistically, AMBRA1 mediates ubiquitylation and proteasomal degradation of cyclin D as a substrate receptor for the cullin 4 E3 ligase complex. Loss of AMBRA1 enhances the growth of lung adenocarcinoma in a mouse model, and low levels of AMBRA1 correlate with worse survival in patients with lung adenocarcinoma. Thus, AMBRA1 regulates cellular levels of cyclin D, and contributes to cancer development and the response of cancer cells to CDK4/6 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33854239      PMCID: PMC8246597          DOI: 10.1038/s41586-021-03474-7

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1 in total

1.  CRL4AMBRA1 targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling.

Authors:  Si-Han Chen; Gwendolyn M Jang; Ruth Hüttenhain; David E Gordon; Dan Du; Billy W Newton; Jeffrey R Johnson; Joseph Hiatt; Judd F Hultquist; Tasha L Johnson; Yi-Liang Liu; Lily A Burton; Jordan Ye; Kurt M Reichermeier; Robert M Stroud; Alexander Marson; Jayanta Debnath; John D Gross; Nevan J Krogan
Journal:  EMBO J       Date:  2018-08-30       Impact factor: 11.598

  1 in total
  26 in total

Review 1.  CRISPR in cancer biology and therapy.

Authors:  Alyna Katti; Bianca J Diaz; Christina M Caragine; Neville E Sanjana; Lukas E Dow
Journal:  Nat Rev Cancer       Date:  2022-02-22       Impact factor: 60.716

Review 2.  A perspective on the role of autophagy in cancer.

Authors:  Aileen R Ariosa; Vikramjit Lahiri; Yuchen Lei; Ying Yang; Zhangyuan Yin; Zhihai Zhang; Daniel J Klionsky
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-09-01       Impact factor: 5.187

Review 3.  Ambra1 in cancer: implications for clinical oncology.

Authors:  Yan-Qiu Qin; Si-Yu Liu; Mei-Ling Lv; Wei-Liang Sun
Journal:  Apoptosis       Date:  2022-08-22       Impact factor: 5.561

4.  Integrated screens uncover a cell surface tumor suppressor gene KIRREL involved in Hippo pathway.

Authors:  Chao Wang; Xu Feng; Dan Su; Zhen Chen; Shimin Wang; Mengfan Tang; Min Huang; Litong Nie; Huimin Zhang; Siting Li; Ling Yin; Randy L Johnson; Traver Hart; Junjie Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-15       Impact factor: 12.779

Review 5.  Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy.

Authors:  Agnieszka K Witkiewicz; Vishnu Kumarasamy; Ioannis Sanidas; Erik S Knudsen
Journal:  Trends Cancer       Date:  2022-05-20

Review 6.  The E3 Ubiquitin Ligase Fbxo4 Functions as a Tumor Suppressor: Its Biological Importance and Therapeutic Perspectives.

Authors:  Shuo Qie
Journal:  Cancers (Basel)       Date:  2022-04-25       Impact factor: 6.575

Review 7.  CDK4 and CDK6 kinases: From basic science to cancer therapy.

Authors:  Anne Fassl; Yan Geng; Piotr Sicinski
Journal:  Science       Date:  2022-01-14       Impact factor: 63.714

8.  Insights from the degradation mechanism of cyclin D into targeted therapy of the cancer cell cycle.

Authors:  Maiwen Caudron-Herger; Sven Diederichs
Journal:  Signal Transduct Target Ther       Date:  2021-08-19

Review 9.  Ubiquitin ligases in cancer: Functions and clinical potentials.

Authors:  Shanshan Duan; Michele Pagano
Journal:  Cell Chem Biol       Date:  2021-05-10       Impact factor: 9.039

Review 10.  Cell cycle on the crossroad of tumorigenesis and cancer therapy.

Authors:  Jing Liu; Yunhua Peng; Wenyi Wei
Journal:  Trends Cell Biol       Date:  2021-07-22       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.